SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Montorsi F.)
 

Sökning: WFRF:(Montorsi F.) > Observational study...

Observational study on time on treatment with abiraterone and enzalutamide

Fallara, Giuseppe (författare)
Uppsala universitet,Urologkirurgi,IRCCS Osped San Raffaele, Unit Urol URI, Div Expt Oncol, Milan, Italy.;Univ Vita Salute San Raffaele, Milan, Italy.
Franck Lissbrant, Ingela, 1969 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper, Avdelningen för onkologi,Institute of Clinical Sciences, Department of Oncology,Univ Göteborg, Sahlgrenska Acad, Inst Clin Sci, Dept Oncol, Gothenburg, Sweden.
Styrke, Johan (författare)
Umeå universitet,Urologi och andrologi,Umeå Univ, Dept Surg & Perioperat Sci Urol & Androl, Umeå, Sweden.
visa fler...
Montorsi, F. (författare)
IRCCS Osped San Raffaele, Unit Urol URI, Div Expt Oncol, Milan, Italy.;Univ Vita Salute San Raffaele, Milan, Italy.
Garmo, Hans (författare)
Uppsala universitet,Uppsala kliniska forskningscentrum (UCR),Institutionen för kirurgiska vetenskaper
Stattin, Pär (författare)
Uppsala universitet,Urologkirurgi
visa färre...
 (creator_code:org_t)
2020-12-28
2020
Engelska.
Ingår i: Plos One. - SAN FRANCISCO USA : Public Library of Science (PLoS). - 1932-6203. ; 15:12
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Introduction The aim of this study was to assess time on treatment with abiraterone and enzalutamide, two androgen receptor targeted (ART) drugs, the impact on time on treatment of time interval without drug supply between prescription fillings, and adherence to treatment. Material and methods By use of data from The National Prostate Cancer Register, The Prescribed Drug Registry and the Patient Registry, time on treatment with the abiraterone and enzalutamide was analyzed in all men with castration resistant prostate cancer (CRPC) in Sweden 2015-2019. Three time intervals between consecutive fillings, i.e. time without drug supply, were assessed. Adherence to the treatment was evaluated by use of the Medication Possession Ratio. Kaplan Meier analysis and multivariable Cox regression model were used to assess factors affecting time on treatment. Results Between January 2015 and October 2019, 1803 men filled a prescription for abiraterone and 4 534 men filled a prescription for enzalutamide. With a time interval of 30 days or less between two fillings, median time on treatment was 4.9 months (IQR 2.6-11.7) for abiraterone and 8.0 months (IQR 3.6-16.4) for enzalutamide. In sensitivity analyses, allowing for no more than 14 days without drug supply between fillings, median time on treatment was 3.9 months (IQR 2.1-9.0) for abiraterone and 5.9 months (IQR 2.8-12.1) for enzalutamide. Allowing for any time period without drug between fillings, median time on treatment was 5.7 months (IQR 2.7-14.0) for abiraterone and 9.8 months (IQR 4.4-21.0) for enzalutamide. Adherence to treatment was above 90% for both drugs. Conclusion Time on treatment with abiraterone and enzalutamide was shorter in clinical practice than in randomized controlled trials and varied almost two-fold with time interval without drug. Adherence to treatment was high. The main limitation of our study was the lack of data on use of chemotherapy.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine -- Cancer and Oncology (hsv//eng)

Nyckelord

resistant prostate-cancer
medication adherence
survival analysis
double-blind
acetate
men
chemotherapy
register
prednisone
experience
Science & Technology - Other Topics
RESISTANT PROSTATE-CANCER

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

  • Plos One (Sök värdpublikationen i LIBRIS)

Till lärosätets databas

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy